Therapeutic Areas
Oncology and Hemato-Oncology Autoimmunity Transplants
At Iclos we specialize in the development and marketing of products in the areas with the greatest investments in research worldwide. Both biotechnological and chemical synthesis drugs targeted to specific molecular targets for the treatment of complex conditions in the areas of oncology, autoimmunity, transplants and orphan diseases.
Product Guarantee
Production Areas
We understand that developing efficient manufacturing processes that meet strict quality criteria is a key element for success in highly competitive markets. That is why Iclos have encouraged audit processes from the very beginning. Our solids plant has been continuously inspected and approved by the European Medicines Agency (EMA) from 2008 to this date with excellent results. We are also certified by the most demanding regulatory bodies in Latin America: INVIMA (Colombia), DIGEMID (Peru), ANMAT (Argentina) and ANVISA (Brazil). Our facilities and processes are also supported by the Ministry of Public Health of the Eastern Republic of Uruguay (MSP).
Vertical Integration
One of Iclos’ greatest competitive advantages is its vertical model operation. This model is characterized by an exhaustive control that covers all stages of production, from cell engineering and culture to the production of active pharmaceutical ingredients (biotechnological) and the manufacture of finished products.
Academic Collaboration
We understand the importance of interaction with other institutions to drive innovation. For this reason, we have forged relationships with different stakeholders of the scientific and technological system of Argentina and Uruguay, such as the Universidad Nacional del Litoral, Santa Fe, Argentina and the Pasteur Institute of Montevideo, Montevideo, Uruguay.
Specific agreements address different aspects related to the development of new products or control of production processes. A success story is the development of Enerceptan together with the Universidad National del Litoral.